Genetic GLP-1 Resistance Could Explain Uneven Ozempic Responses
Stanford-led research links PAM gene variants to GLP-1 resistance, where higher GLP-1 levels do not translate to better blood-sugar control, helping explain why roughly 10% of people respond poorly to Ozempic- and Wegovy-like drugs; the findings point toward precision medicine and may favor longer-acting GLP-1 therapies or alternatives for those with the variants.